Bill
S 2036
Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.
2026-2027 Regular Session
Introduced by Vince Polistina and 1 co-sponsor
New Jersey bill would classify xylazine as Schedule III drug to combat its spread in illicit drug supplies, though enforcement alone may not address underlying addiction and overdose risks.
Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee